In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of GlaxoSmithKline plc
(NYSE:GSK), nVent Electric PLC (NYSE:NVT), Dana Incorporated
(NYSE:DAN), FMC Corporation (NYSE:FMC), Qualys, Inc. (NASDAQ:QLYS),
and Affiliated Managers Group, Inc. (NYSE:AMG), including updated
fundamental summaries, consolidated fiscal reporting, and
fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
GSK DOWNLOAD: http://Capital-Review.com/register/?so=GSK
NVT DOWNLOAD: http://Capital-Review.com/register/?so=NVT DAN
DOWNLOAD: http://Capital-Review.com/register/?so=DAN FMC DOWNLOAD:
http://Capital-Review.com/register/?so=FMC QLYS DOWNLOAD:
http://Capital-Review.com/register/?so=QLYS AMG DOWNLOAD:
http://Capital-Review.com/register/?so=AMG
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine
GlaxoSmithKline plc (NYSE:GSK), nVent Electric PLC (NYSE:NVT), Dana
Incorporated (NYSE:DAN), FMC Corporation (NYSE:FMC), Qualys, Inc.
(NASDAQ:QLYS), and Affiliated Managers Group, Inc. (NYSE:AMG) on a
fundamental level and outlines the overall demand for their
products and services in addition to an in-depth review of the
business strategy, management discussion, and overall direction
going forward. Several excerpts from the recently released reports
are available to today's readers below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. All information in
this release was accessed February 28th, 2019. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
GLAXOSMITHKLINE PLC (GSK) REPORT OVERVIEW
GlaxoSmithKline plc's Recent Financial
Performance
For the three months ended September 30th, 2018
vs September 30th, 2017, GlaxoSmithKline plc reported revenue of
$10,543.88MM vs $10,268.06MM (up 2.69%) and analysts estimated
basic earnings per share $0.75 vs $0.65 (up 15.65%). For the twelve
months ended December 31st, 2018 vs December 31st, 2017,
GlaxoSmithKline plc reported revenue of $41,139.87MM vs
$38,903.72MM (up 5.75%) and analysts estimated basic earnings per
share $1.97 vs $0.81 (up 143.49%). Analysts expect earnings to be
released on April 24th, 2019. The report will be for the fiscal
period ending March 31st, 2019. The reported EPS for the same
quarter last year was $0.68. The estimated EPS forecast for the
next fiscal year is $3.03 and is expected to report on February
5th, 2020.
To read the full GlaxoSmithKline plc (GSK) report, download it
here:
http://Capital-Review.com/register/?so=GSK
-----------------------------------------
NVENT ELECTRIC PLC (NVT) REPORT OVERVIEW
nVent Electric's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, nVent Electric reported revenue of
$568.10MM vs $541.90MM (up 4.83%) and analysts estimated basic
earnings per share $0.38 vs $0.87 (down 56.32%). For the twelve
months ended December 31st, 2018 vs December 31st, 2017, nVent
Electric reported revenue of $2,213.60MM vs $2,097.90MM (up 5.52%)
and analysts estimated basic earnings per share $1.29 vs $2.02
(down 36.14%). Analysts expect earnings to be released on May 2nd,
2019. The report will be for the fiscal period ending March 31st,
2019. The estimated EPS forecast for the next fiscal year is $2.05
and is expected to report on January 30th, 2020.
To read the full nVent Electric PLC (NVT) report, download it
here:
http://Capital-Review.com/register/?so=NVT
-----------------------------------------
DANA INCORPORATED (DAN) REPORT OVERVIEW
Dana's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Dana reported revenue of $1,973.00MM vs
$1,837.00MM (up 7.40%) and analysts estimated basic earnings per
share $0.69 vs -$0.75. For the twelve months ended December 31st,
2018 vs December 31st, 2017, Dana reported revenue of $8,143.00MM
vs $7,209.00MM (up 12.96%) and analysts estimated basic earnings
per share $2.94 vs $0.72 (up 308.33%). Analysts expect earnings to
be released on April 29th, 2019. The report will be for the fiscal
period ending March 31st, 2019. Reported EPS for the same quarter
last year was $0.75. The estimated EPS forecast for the next fiscal
year is $3.54 and is expected to report on February 21st, 2020.
To read the full Dana Incorporated (DAN) report, download it
here:
http://Capital-Review.com/register/?so=DAN
-----------------------------------------
FMC CORPORATION (FMC) REPORT OVERVIEW
FMC's Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, FMC reported revenue of $1,219.20MM vs
$979.60MM (up 24.46%) and basic earnings per share $0.24 vs $3.95
(down 93.92%). For the twelve months ended December 31st, 2018 vs
December 31st, 2017, FMC reported revenue of $4,727.80MM vs
$2,878.60MM (up 64.24%) and analysts estimated basic earnings per
share $3.72 vs $3.99 (down 6.77%). Analysts expect earnings to be
released on May 1st, 2019. The report will be for the fiscal period
ending March 31st, 2019. The reported EPS for the same quarter last
year was $1.84. The estimated EPS forecast for the next fiscal year
is $6.55 and is expected to report on February 10th, 2020.
To read the full FMC Corporation (FMC) report, download it here:
http://Capital-Review.com/register/?so=FMC
-----------------------------------------
QUALYS, INC. (QLYS) REPORT OVERVIEW
Qualys' Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Qualys reported revenue of $74.20MM vs
$62.92MM (up 17.94%) and analysts estimated basic earnings per
share $0.37 vs $0.07 (up 428.57%). For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Qualys reported revenue
of $278.89MM vs $230.83MM (up 20.82%) and analysts estimated basic
earnings per share $1.47 vs $1.08 (up 36.11%). Analysts expect
earnings to be released on May 7th, 2019. The report will be for
the fiscal period ending March 31st, 2019. The reported EPS for the
same quarter last year was $0.22. The estimated EPS forecast for
the next fiscal year is $1.43 and is expected to report on February
11th, 2020.
To read the full Qualys, Inc. (QLYS) report, download it here:
http://Capital-Review.com/register/?so=QLYS
-----------------------------------------
AFFILIATED MANAGERS GROUP, INC. (AMG) REPORT
OVERVIEW
Affiliated Managers Group's Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Affiliated Managers Group reported revenue
of $564.40MM vs $604.10MM (down 6.57%) and analysts estimated basic
earnings per share -$2.88 vs $5.65. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Affiliated Managers
Group reported revenue of $2,378.40MM vs $2,305.00MM (up 3.18%) and
analysts estimated basic earnings per share $4.55 vs $12.30 (down
63.01%). Analysts expect earnings to be released on April 29th,
2019. The report will be for the fiscal period ending March 31st,
2019. The reported EPS for the same quarter last year was $3.92.
The estimated EPS forecast for the next fiscal year is $15.31 and
is expected to report on February 3rd, 2020.
To read the full Affiliated Managers Group, Inc. (AMG) report,
download it here:
http://Capital-Review.com/register/?so=AMG
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Nicole Garrens, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024